Two-fraction HDR brachytherapy achieved durable control in favourable-risk prostate cancer
High-dose-rate brachytherapy using 13.5 Gy twice achieved 81.6% ten-year biochemical control with limited late genitourinary toxicity.
Tag
Worth Attention
Postoperative radiotherapy did not improve survival beyond chemotherapy in pT3N0M0 oesophageal cancer
Adding postoperative radiotherapy to chemotherapy did not significantly improve survival after R0 resection of pT3N0M0 oesophageal squamous cell carcinoma.
Single-fraction lung brachytherapy produced progressive consolidation and fibrotic retraction
Pulmonary consolidation was common after single-fraction interstitial brachytherapy and frequently evolved into progressive retraction during the second year.
ABS defines competencies for endobronchial and esophageal brachytherapy training
The American Brachytherapy Society outlines clinical, procedural, planning and safety competencies for trainees performing endobronchial and esophageal brachytherapy.
MRI deep learning identified oral tongue cancers associated with postoperative radiotherapy benefit
An MRI and pathology-based model identified a poor-risk oral tongue cancer group in which postoperative radiotherapy was associated with improved survival.
Low-dose radiotherapy produced durable benefit in refractory plantar fasciitis
Low-dose radiotherapy produced sustained pain, function and quality-of-life improvement after conservative treatment and shock-wave therapy had failed.
Mean lung dose strongly predicted pneumonitis after adjuvant breast radiotherapy
A mean lung dose threshold of 12.70 grays strongly separated patients who developed radiation pneumonitis after adjuvant breast radiotherapy.
Medial retropharyngeal nodes were involved in 2.95% of non-endemic nasopharyngeal cancers
Medial retropharyngeal nodes were involved in 2.95% of German cases, but no recurrence occurred among patients whose elective volume omitted the region.
Five-fraction prostate and pelvic nodal SBRT showed low late toxicity
After prostate and pelvic nodal SBRT, no grade ≥3 late GU or GI toxicity occurred among 101 patients with high-risk disease.
Cardiac toxicity occurred in 8% after central and ultracentral lung SBRT
Symptomatic grade ≥2 cardiac toxicity occurred in 8% after central or ultracentral lung SBRT, typically developing more than one year after treatment.
Higher-BED palliative radiotherapy improved symptoms in rectal cancer
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
Carbon ion re-irradiation showed feasible salvage outcomes in recurrent pelvic sarcoma
High-dose carbon ion re-irradiation achieved 83.1% 3-year survival with no grade 4 toxicity in recurrent pelvic sarcoma.
Concurrent polatuzumab vedotin and radiotherapy showed no unexpected toxicity in B-cell lymphoma
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.
Twice-weekly 28 Gy whole-breast irradiation showed low toxicity in early breast cancer
Twice-weekly 28 Gy in 5 fractions produced no grade 3 or higher toxicity and 98.8% excellent-to-good cosmesis at 1 year.
Radiotherapy was tolerated without unexpected skin toxicity in epidermolysis bullosa
Four epidermolysis bullosa patients tolerated radiotherapy without greater-than-expected cutaneous toxicity, despite maximum skin dose up to 50.4 Gy.